Valuation LAVA Therapeutics

Stocks

Delayed Nasdaq 16:00:00 2025-11-20 EST			5-day change	1st Jan Change
1.740 ^USD	-3.87%		-.--%	-

11-21	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
11-21	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024
Market Cap ¹	141.8	92.01	41.54	25.01
Change	-	-35.1%	-54.86%	-39.79%
Enterprise Value (EV) ¹	13.43	-35.41	-47.72	-46.28
Change	-	-363.69%	-34.78%	3.01%
P/E	-2.4x	-2.84x	-1.01x	-1.02x
PBR	1.2x	1.07x	0.81x	0.9x
PEG	-	0.1x	-0x	0x
Capitalization / Revenue	28,353,092x	4,745,078x	6,136,321x	2,087,300x
EV / Revenue	-	-	-	-
EV / EBITDA	-0.31x	1.03x	1.12x	1.83x
EV / EBIT	-0.3x	1.02x	1.1x	1.79x
EV / FCF	-	-	-	-
FCF Yield	-	-	-	-
Dividend per Share ³	-	-	-	-
Rate of return	-	-	-	-
EPS ³	-2.295	-1.231	-1.57	-0.9359
Distribution rate	-	-	-	-
Net sales	5	19.39	6.769	11.98
EBITDA ¹	-44.02	-34.33	-42.64	-25.33
EBIT ¹	-44.35	-34.84	-43.25	-25.79
Net income ¹	-45.35	-31.91	-41.97	-25.11
Net Debt ¹	-128.3	-127.4	-89.26	-71.3
Reference price ³	5.500	3.500	1.580	0.951
Nbr of stocks (in thousands)	25,776	26,289	26,289	26,299
Announcement Date	3/24/22	4/11/23	3/20/24	3/28/25

¹USD in Million²EUR in Million³USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
LAVA THERAPEUTICS	-	-	-	-	45.77M
LONZA GROUP AG	32.49x	5.84x	17.49x	1%	48.01B
REVOLUTION MEDICINES, INC.	-21.22x	242.27x	-22.87x	-.--%	44.44B
IQVIA HOLDINGS INC.	33.38x	3.24x	14x	-.--%	42.67B
BEONE MEDICINES AG	46.04x	5.32x	29.1x	-.--%	39.96B
CELLTRION, INC.	27.78x	8.36x	21.2x	0.41%	32.75B
MEDPACE HOLDINGS, INC.	33.6x	5.5x	25x	-.--%	16.49B
EUROFINS SCIENTIFIC SE	23.74x	2.07x	8.99x	1.13%	14.38B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	75.11x	3.97x	15.39x	-.--%	13.4B
Average	31.36x	34.57x	13.54x	0.32%	28.02B
Weighted average by Cap.	26.55x	46.98x	12.00x	0.31%